The development of the GLP1R/GIPR dual agonist tirzepatide brought new insights into the role of GIP in the treatment of T2D and obesity because it can reduce both plasma glucose and glycated haemoglobin more effectively than the GLP1R agonist semaglutide. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.